Protective Effect of Crocin on Immune Checkpoint Inhibitors-Related Myocarditis Through Inhibiting NLRP3 Mediated Pyroptosis in Cardiomyocytes via NF-κB Pathway

References

• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–249. doi:10.1146/annurev-pathol-042020-042741
   PubMed Web of Science ®Google Scholar
• Singh S, Hassan D, Aldawsari HM, Molugulu N, Shukla R, Kesharwani P. Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discov Today. 2020;25(1):223–229. doi:10.1016/j.drudis.2019.11.003
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors. JAMA Oncol. 2018;4(12):1721–1728. doi:10.1001/jamaoncol.2018.3923
   PubMed Web of Science ®Google Scholar
• Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. JAMA. 2018;320(16):1702–1703. doi:10.1001/jama.2018.13995
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481
   PubMed Web of Science ®Google Scholar
• Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–1353. doi:10.1001/jamaoncol.2016.1051
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2(4):e000247. doi:10.1136/esmoopen-2017-000247
   PubMed Web of Science ®Google Scholar
• Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–1764. doi:10.1016/j.jacc.2018.02.037
   PubMed Web of Science ®Google Scholar
• Chen DY, Huang WK, Chien-Chia Wu V, et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a review when cardiology meets immuno-oncology. J Formos Med Assoc 2020;119(10):1461–1475. doi:10.1016/j.jfma.2019.07.025
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755. doi:10.1056/NEJMoa1609214
   PubMed Web of Science ®Google Scholar
• Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854–868. doi:10.1093/cvr/cvz026
   PubMed Web of Science ®Google Scholar
• Salem JE, Allenbach Y, Vozy A, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377–2379. doi:10.1056/NEJMc1901677
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157(5):1013–1022. doi:10.1016/j.cell.2014.04.007
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Z, Ruan J, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535(7610):153–158. doi:10.1038/nature18629
   PubMed Web of Science ®Google Scholar
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417–426. doi:10.1016/S1097-2765(02)00599-3
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–665. doi:10.1038/nature15514
   PubMed Web of Science ®Google Scholar
• Guo H, Callaway JB, Ting JPY. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677–687. doi:10.1038/nm.3893
   PubMed Web of Science ®Google Scholar
• Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol. 2011;166(1):1–15. doi:10.1111/j.1365-2249.2011.04440.x
   PubMed Web of Science ®Google Scholar
• Theivanthiran B, Evans KS, DeVito NC, et al. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Invest. 2020;130(5):2570–2586. doi:10.1172/JCI133055
   PubMed Web of Science ®Google Scholar
• Quagliariello V, De Laurentiis M, Cocco S, et al. NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells. Int J Mol Sci. 2020;21(20):7802. doi:10.3390/ijms21207802
   PubMed Web of Science ®Google Scholar
• Bukhari SI, Manzoor M, Dhar MK. A comprehensive review of the pharmacological potential of Crocus sativus and its bioactive apocarotenoids. Biomed Pharmacother. 2018;98:733–745. doi:10.1016/j.biopha.2017.12.090
   PubMed Web of Science ®Google Scholar
• Hashemzaei M, Mamoulakis C, Tsarouhas K, et al. Crocin: a fighter against inflammation and pain. Food Chem Toxicol. 2020;143:111521.
   PubMed Web of Science ®Google Scholar
• Hashemzaei M, Rezaee R, Nabatzehi M, et al. Anti-hypertensive effect of crocin and hesperidin combination in high-fat diet treated rats. Exp Ther Med. 2020;19(6):3840–3844. doi:10.3892/etm.2020.8650
   PubMed Web of Science ®Google Scholar
• Korani S, Korani M, Sathyapalan T, Sahebkar A. Therapeutic effects of Crocin in autoimmune diseases: a review. Bio Factors Oxf Engl. 2019;45(6):835–843. doi:10.1002/biof.1557
   PubMed Web of Science ®Google Scholar
• Hatziagapiou K, Kakouri E, Lambrou GI, Bethanis K, Tarantilis PA. Antioxidant properties of Crocus sativus L. and its constituents and relevance to neurodegenerative diseases; focus on Alzheimer’s and Parkinson’s disease. Curr Neuropharmacol. 2019;17(4):377–402. doi:10.2174/1570159X16666180321095705
   PubMed Web of Science ®Google Scholar
• Jin W, Zhang Y, Xue Y, et al. Crocin attenuates isoprenaline-induced myocardial fibrosis by targeting TLR4/NF-κB signaling: connecting oxidative stress, inflammation, and apoptosis. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(1):13–23. doi:10.1007/s00210-019-01704-4
   PubMed Web of Science ®Google Scholar
• Bockstahler M, Fischer A, Goetzke CC, et al. Heart-specific immune responses in an animal model of autoimmune-related myocarditis mitigated by an immunoproteasome inhibitor and genetic ablation. Circulation. 2020;141(23):1885–1902. doi:10.1161/CIRCULATIONAHA.119.043171
   PubMed Web of Science ®Google Scholar
• Qiu Y, Ma Y, Jiang M, et al. Melatonin alleviates LPS-induced pyroptotic cell death in human stem cell-derived cardiomyocytes by activating autophagy. Stem Cells Int. 2021;2021:8120403. doi:10.1155/2021/8120403
   PubMed Web of Science ®Google Scholar
• Qiu Z, He Y, Ming H, Lei S, Leng Y, Xia ZY. Lipopolysaccharide (LPS) aggravates high glucose- and hypoxia/reoxygenation-induced injury through activating ROS-dependent NLRP3 inflammasome-mediated pyroptosis in H9C2 cardiomyocytes. J Diabetes Res. 2019;2019:8151836. doi:10.1155/2019/8151836
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768. doi:10.1200/JCO.2017.77.6385
   PubMed Web of Science ®Google Scholar
• Palaskas N, Lopez‐Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757.
   PubMed Web of Science ®Google Scholar
• Ji C, Roy MD, Golas J, et al. Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors. Clin Cancer Res. 2019;25(15):4735–4748. doi:10.1158/1078-0432.CCR-18-4083
   PubMed Web of Science ®Google Scholar
• Wang J, Okazaki IM, Yoshida T, et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol. 2010;22(6):443–452. doi:10.1093/intimm/dxq026
   PubMed Web of Science ®Google Scholar
• Grabie N, Gotsman I, DaCosta R, et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation. 2007;116(18):2062–2071. doi:10.1161/CIRCULATIONAHA.107.709360
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in ctla-4. Science. 1995;270(5238):985–988. doi:10.1126/science.270.5238.985
   PubMed Web of Science ®Google Scholar
• Michel L, Helfrich I, Hendgen-Cotta UB, et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J. 2021;43(4):ehab430.
   Web of Science ®Google Scholar
• Liu X, Zhang X, Ye L, Yuan H. Protective mechanisms of berberine against experimental autoimmune myocarditis in a rat model. Biomed Pharmacother. 2016;79:222–230. doi:10.1016/j.biopha.2016.02.015
   PubMed Web of Science ®Google Scholar
• Baradaran Rahim V, Khammar MT, Rakhshandeh H, Samzadeh-Kermani A, Hosseini A, Askari VR. Crocin protects cardiomyocytes against LPS-induced inflammation. Pharmacol Rep. 2019;71(6):1228–1234. doi:10.1016/j.pharep.2019.07.007
   PubMed Web of Science ®Google Scholar
• Zhao W, Ma L, Cai C, Gong X. Caffeine Inhibits NLRP3 inflammasome activation by suppressing MAPK/NF-κB and A2aR signaling in LPS-induced THP-1 macrophages. Int J Biol Sci. 2019;15(8):1571–1581. doi:10.7150/ijbs.34211
   PubMed Web of Science ®Google Scholar
• Boaru SG, Borkham-Kamphorst E, Van de Leur E, Lehnen E, Liedtke C, Weiskirchen R. NLRP3 inflammasome expression is driven by NF-κB in cultured hepatocytes. Biochem Biophys Res Commun. 2015;458(3):700–706. doi:10.1016/j.bbrc.2015.02.029
   PubMed Web of Science ®Google Scholar
• Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol. 2011;12(8):695–708. doi:10.1038/ni.2065
   PubMed Web of Science ®Google Scholar
• Mitchell S, Vargas J, Hoffmann A. Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med. 2016;8(3):227–241. doi:10.1002/wsbm.1331
   PubMed Web of Science ®Google Scholar
• Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33–40. doi:10.1038/nrd2781
   PubMed Web of Science ®Google Scholar
• Cheong R, Hoffmann A, Levchenko A. Understanding NF-kappaB signaling via mathematical modeling. Mol Syst Biol. 2008;4:192. doi:10.1038/msb.2008.30
   PubMed Web of Science ®Google Scholar
• Kearns JD, Hoffmann A. Integrating computational and biochemical studies to explore mechanisms in NF-κB Signaling. J Biol Chem. 2009;284(9):5439–5443. doi:10.1074/jbc.R800008200
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh H, Mehri S, Heshmati A, Ramezani M, Sahebkar A, Abnous K. Proteomic screening of molecular targets of crocin. DARU J Pharm Sci. 2014;22(1):5. doi:10.1186/2008-2231-22-5
   Web of Science ®Google Scholar
• Ochiai T, Ohno S, Soeda S, Tanaka H, Shoyama Y, Shimeno H. Crocin prevents the death of rat pheochromyctoma (PC-12) cells by its antioxidant effects stronger than those of alpha-tocopherol. Neurosci Lett. 2004;362(1):61–64. doi:10.1016/j.neulet.2004.02.067
   PubMed Web of Science ®Google Scholar
• Liang Y, Zheng B, Li J, et al. Crocin ameliorates arsenic trioxide‑induced cardiotoxicity via Keap1-Nrf2/HO-1 pathway: reducing oxidative stress, inflammation, and apoptosis. Biomed Pharmacother. 2020;131:110713. doi:10.1016/j.biopha.2020.110713
   PubMed Web of Science ®Google Scholar